Nurix Therapeutics, Inc. 4

CSO Gwenn Hansen sold 5,394 shares of Nurix Therapeutics common stock at about $20 per share on June 25, 2026, leaving her with 115,005 shares.

On June 25, 2026, Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen sold 5,394 shares of the company’s common stock at approximately $20.00 per share, for an estimated total value of about $108,000, pursuant to a pre-established Rule 10b5-1 trading plan. Following this transaction, Hansen beneficially owns 115,005 shares of Nurix common stock, which at the same implied price are worth roughly $2.3 million. The sale appears to be a discretionary portfolio management or liquidity event executed under an automated plan rather than an ad hoc trade, but it still modestly reduces her direct equity exposure to the company.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

sec

Accession

0001817160-26-000010

Alert Tier

5